This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Ross J. Simpson, Jr, MD,PhD

JAMA. 2001;286:91-93.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of THE JOURNAL, Albert and colleagues¹ present the main results of the Pravastatin Inflammation/CRP Evaluation (PRINCE) study, a randomized clinical trial and prospective cohort study evaluating the effects of pravastatin on levels of high sensitivity C-reactive protein (CRP). The investigators randomly assigned men and women with elevated low-density lipoprotein cholesterol (LDL-C) levels and no apparent coronary disease to receive placebo or pravastatin to assess the change in CRP levels at 24 weeks independently of the change in lipids. An additional cohort of patients with established coronary disease received open label pravastatin to determine the effect on CRP among these patients as well.

In the primary analysis of patients who provided at least baseline and 12-week blood samples and had sufficient data for follow-up, pravastatin, compared with placebo, resulted in a 16.9% reduction (absolute reduction of 0.02 mg/dL) in CRP levels at 24 . . . [Full Text of this Article]

Author Affiliation: Cardiology Section, University of North Carolina, Chapel Hill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effect of Statin Therapy on C-Reactive Protein Levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A Randomized Trial and Cohort Study
Michelle A. Albert, Ellie Danielson, Nader Rifai, Paul M Ridker, and for the PRINCE Investigators
JAMA. 2001;286(1):64-70.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Poor Predictive Value of High-Sensitivity C-Reactive Protein Indicates Need for Reassessment
Levinson et al.
Clin. Chem. 2004;50:1733-1735.
FULL TEXT  

Rofecoxib, a COX-2 Inhibitor, Lowers C-Reactive Protein and Interleukin-6 Levels in Patients With Acute Coronary Syndromes
Monakier et al.
Chest 2004;125:1610-1615.
ABSTRACT | FULL TEXT  

Joint Effects of C-Reactive Protein and Glycated Hemoglobin in Predicting Future Cardiovascular Events of Patients With Advanced Atherosclerosis
Schillinger et al.
Circulation 2003;108:2323-2328.
ABSTRACT | FULL TEXT  

Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels
Rizos et al.
ANGIOLOGY 2002;53:273-277.
ABSTRACT  

Refractory angina pectoris: Mechanism and therapeutic options
Kim et al.
J Am Coll Cardiol 2002;39:923-934.
ABSTRACT | FULL TEXT  

Pravastatin Reduces CRP Levels
Journal Watch Cardiology 2001;2001:2-2.
FULL TEXT  

Statins Reduce C-Reactive Protein Levels
JWatch General 2001;2001:1-1.
FULL TEXT